Technology Platforms

Conjugation Chemistry & Linkers

Linker design and functional handles for joining oligos, peptides, proteins, payloads, chelators, and lipid materials.

How this supports a project

A conjugation plan must define both molecules, both attachment sites, the reaction sequence, the intended role of the linker, and how the final conjugate will be characterized. A handle name or nominal linker length is not a complete specification.

Define the complete connection, not only the linker

The first molecule, second molecule, attachment position on each, and reaction order determine which handles and protecting groups are usable. Amine-, thiol-, click-, enzymatic-, and other conjugation routes create different site distributions, bond structures, side reactions, and purification demands.

Spacer length, PEG or alkyl content, rigidity, charge, hydrophilicity, branching, and stable or cleavable motifs can change solubility, aggregation, accessibility, and final-conjugate behavior. Published studies also show that linker properties and conjugation site can interact, so material selection must be evaluated on the complete conjugate.

Typical conjugation-planning workflow

1

Define both molecular partners

Provide exact identities or structures, material forms, available amounts, formulations, and groups that must retain their function.

2

Choose attachment sites

Identify native or engineered amines, thiols, azides, alkynes, tags, or other positions and decide whether a distribution or a site-defined product is required.

3

Set linker function

State whether the linker provides spacing, hydrophilicity, rigidity, branching, triggered release, stable attachment, a purification handle, or a combination of these roles.

4

Plan handles and reaction order

Match orthogonal functional groups, protecting groups, solvent and buffer limits, concentrations, coupling order, and intermediate isolation.

5

Prepare and characterize intermediates

Confirm structure, identity, purity, reactive-handle content, residual reagents, stability, and storage for each isolated linker or conjugation-ready intermediate.

6

Characterize the final conjugate

Measure loading or stoichiometry, site or distribution, free component, aggregation where relevant, purity, bond stability or release, and retained target function.

Inputs for platform review

Partner A and partner B

Exact structures or identities, molecular formats, quantities, formulations, and sensitive functional groups.

Attachment strategy

Target residues or positions, random or site-defined format, acceptable heterogeneity, and required bond type.

Linker requirements

Length range, composition, rigidity, hydrophilicity, charge, branching, stability or release mechanism, and terminal handles.

Process constraints

Permitted pH, temperature, buffers, organic solvent, concentration, reaction time, purification method, and storage limits.

Final-product tests

Identity, purity, loading, site confirmation or distribution, free components, aggregation, stability or release, and retained biological or binding function.

Where this platform applies

This platform covers linker and handle selection, custom linker synthesis, conjugation-ready intermediates, and chemistry planning. It does not guarantee conjugation yield, site specificity, homogeneity, release rate, stability in a biological matrix, solubility, biological activity, safety, clinical suitability, or regulatory status. Those attributes must be measured on the final conjugate under project-relevant conditions.

Core considerations

  • PEG, alkyl, and rigid spacer design
  • NHS, maleimide, azide, alkyne, DBCO, BCN, TCO, and tetrazine handles
  • Cleavable and stable linker selection

Related catalog and technical pages

Sources

  1. 1.A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems (Journal of the American Chemical Society, 2004)
  2. 2.Long-term stabilization of maleimide-thiol conjugates (Bioconjugate Chemistry, 2015)
  3. 3.Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs (Journal of Pharmaceutical Sciences, 2020)
  4. 4.Glycan-Mediated Technology for Obtaining Homogeneous Site-Specific Conjugated Antibody-Drug Conjugates: Synthesis and Analytical Characterization by Using Complementary Middle-up LC/HRMS Analysis (Analytical Chemistry, 2020)